首页 | 本学科首页   官方微博 | 高级检索  
     

新型重组纤维蛋白原受体拮抗剂的表达、纯化及活性研究
引用本文:姚佳, 杨坤, 杨建波, 华子春, 杨洁. 新型重组纤维蛋白原受体拮抗剂的表达、纯化及活性研究[J]. 中国药科大学学报, 2005, 36(2): 173-178.
作者姓名:姚佳  杨坤  杨建波  华子春  杨洁
作者单位:1.南京大学生命科学院医药生物技术国家重点实验室
基金项目:国家自然科学基金,教育部高校骨干教师资助计划
摘    要:
目的:构建两个预期能够成为纤维蛋白原受体拮抗剂的重组融合蛋白。方法:人工合成北美水蛭素Decorsin的基因序列,利用基因工程的方法构建两个重组蛋白,分别是AnnV D39:AnnexinV加上Decorsin全序列和AnnV- D2 7:AnnexinV加上Decorsin的羧基端2 7个氨基酸序列。在AnnV D39的AnnexinV和Decorsin序列之间加入了由10个氨基酸组成的连接肽GGGGSGGGGS。利用质粒pET -2 8(a +)作为载体,将上述融合蛋白在大肠杆菌E coliBL2 1(DE3)中以包涵体的形式进行高效表达,纯化后,进行抗血小板聚集活性测试。结果:基因表达的产物在变性条件下用DEAE -Cellulose5 2和SepharoseCL -4B层析纯化。随后进行的血小板聚集分析表明,An nV D39具有良好的抗血小板凝集活性,而AnnV D2 7没有显示相似活性。结论:AnnV- D39作为一种新的纤维蛋白原受体抑制剂显示了良好的活性,而Annv- D2 7需要进行进一步的修饰。

关 键 词:纤维蛋白原受体拮抗剂  融合蛋白  抗血小板聚集活性
文章编号:1000-5048(2005)02-0173-06
修稿时间:2004-06-22

Expression, Purification,and Activity Assay of Two New Recombinant Fibrinogen Receptor Antagonists
YAO Ji,YANG Kun,YANG Jian-Bo,HUA Zi-Chun,YANG Jie. Expression, Purification,and Activity Assay of Two New Recombinant Fibrinogen Receptor Antagonists[J]. Journal of China Pharmaceutical University, 2005, 36(2): 173-178
Authors:YAO Ji  YANG Kun  YANG Jian-Bo  HUA Zi-Chun  YANG Jie
Abstract:
AIM:To construct and characterize two recombinant p roteins, which are expected to be antagonists of fibrinogen receptors. METHOD:The gene sequence of decorsin which is extracted from a kind of North American leeches was synthesized.Two recombinant proteins,Annexin V plus decorsin (AnnV-D39) and Annexin V plus the carboxyl terminal 27 amino acids variant of decorsin (AnnV-D27), were constructed. And a 10 amino acids linke r peptide of GGGGSGGGGS was inserted between annexin V and decorsin in AnnV-D39 . Using pET-28 (a+) as an expressing vector, both two recombinant proteins we re expressed in E. coli BL21(DE3) with high efficiency as inclusion bodies .RESULT:The expression products were purified by DEAE-Cellulos e 52 and Sepharose CL-4B chromatography under denaturing condition.The results of platelet aggregation assay (PAA) show that AnnV-D39 shows a good anti -platelet aggregation activity. However, AnnV-D27 shows no such activities i n any PAA test .CONCLUSION:AnnV-D39 showed a good anti-platelet aggregation a c tivity as a promising antagonist of fibrinogen receptor, while Annv-D27 needs further modification.
Keywords:Antagonist of fibrinogen receptor  Recombinant prot ein  Anti-platelet aggregation activity
本文献已被 CNKI 维普 万方数据 等数据库收录!
点击此处可从《中国药科大学学报》浏览原始摘要信息
点击此处可从《中国药科大学学报》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号